As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

monoclonal antibodies, such as cetuximab and panitumumab, directed against the extracellular domain of EGFR, and tyrosine kinase inhibitors, like gefitinib and erlotinib, which block the kinase ...

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of ...

Binders with varying binding strengths were identified for six targets, including PD-L1, HER2, EGFR(S468R), ACVR2A/B, FZD7, and ALK7. Notably, the team successfully designed antibodies targeting ...

The U.S. Patent and Trademark Office issued a patent for NT219 used in combination with EGFR antibodies for treating cancer patients who have acquired resistance to EGFR therapies. This latest U.S ...

De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...